V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10226227 | 10042779 | 1.78 | 78 | Palliative (P) | 2021-03-22 | 2021-04-17 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | null | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 101370729 |
| 10227216 | 10042781 | null | null | Disease modification (D) | 2021-03-05 | 2021-04-23 | CVP | 02 | null | DABRAFENIB | 100398263 |
| 10228933 | 10042785 | 1.76 | null | null | 2019-06-19 | 2019-06-19 | AVELUMAB + AXITINIB | 02 | N | THALIDOMIDE | 101397469 |
| 10229199 | 10042786 | 1.55 | 72.5 | Curative (C) | 2022-01-18 | 2022-01-20 | THALIDOMIDE | 02 | N | VINCRISTINE | 101862482 |
| 10230149 | 10042787 | 1.7 | 72 | Curative (C) | 2019-07-08 | 2019-07-10 | Obinutuzumab | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100162175 |
| 10232432 | 10042789 | 1.77 | 73.5 | null | 2019-06-03 | 2019-10-28 | null | 99 | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101383605 |
| 10234725 | 10042790 | 0 | 85.5 | Palliative (P) | 2017-07-21 | 2017-07-29 | null | 02 | null | LENVATINIB | 100586677 |
| 10237486 | 10042792 | 0 | null | Palliative (P) | 2020-12-26 | 2021-01-02 | LUTETIUM-177 | 02 | N | CABOZANTINIB | 101154598 |
| 10238580 | 10042794 | 0 | 69 | null | 2022-05-09 | 2022-05-17 | Bortezomib + Cyclophos + Dex | 02 | null | PACLITAXEL + TRASTUZUMAB | 100616202 |
| 10239929 | 10042795 | 1.68 | 42.35 | Palliative (P) | null | 2022-02-24 | Cape+Cisplatin+Trastuzumab Load | 02 | null | FLAIR TRIAL | 101326186 |
| 10240488 | 10042796 | 1.73 | null | 03 | 2019-08-03 | 2019-08-06 | CTD | 01 | N | SORAFENIB | 101791713 |
| 10240910 | 10042797 | 1.62 | 62 | Curative (C) | 2019-04-14 | 2019-04-15 | CYTARABINE + DAUNORUBICIN | null | N | LANREOTIDE | 101674103 |
| 10245092 | 10042800 | 1.75 | 60.4 | null | 2016-01-07 | 2016-01-23 | Bortezomib + Daratumumab | 2 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100537325 |
| 10251295 | 10042802 | 1.73 | 69.6 | null | 2019-08-23 | 2019-08-27 | PEMBROLIZUMAB + PEMETREXED | 02 | N | PARTNER TRIAL | 100189616 |
| 10257579 | 10042804 | 1.74 | 83.2 | Adjuvant (A) | 2020-01-16 | 2020-01-16 | CARBOPLATIN + EPIRUBICIN | N | N | DOXORUBICIN EMBOLISATION | 101654023 |
| 10258053 | 10042806 | 1.8 | 83 | null | 2021-07-13 | 2021-07-17 | CHLVPP | 02 | null | CAPECITABINE + RT | 101354123 |
| 10262908 | 10042808 | 1.76 | 80 | Disease modification (D) | 2014-01-28 | 2014-10-16 | Bendamustine +/- Prednisolone | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL + PERTUZUMAB + TRASTUZUMAB | 101503964 |
| 10266939 | 10042810 | 1.76 | 78.8 | Curative (C) | 2019-02-12 | 2019-03-15 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | N | N | ETOP 13-18 BEAT-MESO TRIAL | 100297623 |
| 10268741 | 10042812 | 0 | 62.8 | Palliative (P) | 2017-01-22 | 2017-01-28 | Cisplatin 100 + RT(H&N) 1 day | 01 | N | CARBOPLATIN + FLUOROURACIL | 100116935 |
| 10269308 | 10042813 | 1.76 | 79.4 | Neo-adjuvant (N) | 2017-08-30 | 2017-09-05 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | FLAIR TRIAL | 100376264 |
| 10273139 | 10042815 | 1.76 | 94.6 | Palliative (P) | 2019-08-14 | 2019-08-25 | FEC + DOCETAXEL + TRASTUZUMAB | 02 | N | SORAFENIB | 100864854 |
| 10273538 | 10042816 | 1.78 | 83 | Curative (C) | 2018-06-08 | 2018-06-15 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | DABRAFENIB | 100113346 |
| 10275478 | 10042820 | 1.83 | 82.1 | Adjuvant (A) | 2019-02-16 | 2019-03-08 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101464786 |
| 10275818 | 10042821 | 1.73 | 94.2 | 03 | 2019-09-10 | 2019-09-29 | NAB PACLITAXEL | 02 | N | CISPLATIN + PEMETREXED | 100891855 |
| 10275881 | 10042822 | 1.79 | 82 | Curative (C) | 2020-07-08 | 2020-07-24 | Rituximab + Venetoclax | 02 | null | CISPLATIN + ETOPOSIDE | 100035992 |
| 10276577 | 10042825 | 1.71 | 80.1 | Curative (C) | 2020-01-01 | 2020-01-03 | Carboplatin + Liposomal Doxorubicin | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101212845 |
| 10277006 | 10042827 | 1.66 | 83 | Neo-adjuvant (N) | 2017-06-19 | 2017-07-03 | Ixazomib + Lenalidomide | 02 | N | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 101801543 |
| 10277286 | 10042828 | 1.54 | 93.8 | Palliative (P) | 2019-08-26 | 2019-09-02 | FEC + DOCETAXEL | N | null | BORTEZOMIB + DARATUMUMAB | 101098670 |
| 10277622 | 10042831 | 1.6 | 100.2 | Palliative (P) | 2019-12-27 | 2020-01-04 | Sorafenib | 02 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100962482 |
| 10277714 | 10042832 | 1.76 | 65.3 | Palliative (P) | 2017-04-19 | 2017-04-19 | Thalidomide 50mg | 02 | N | PENTOSTATIN + RITUXIMAB | 101468707 |
| 10278046 | 10042833 | 1.62 | 62.4 | Neo-adjuvant (N) | 2021-06-09 | 2021-06-24 | AZACITIDINE + VENETOCLAX | 02 | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100142657 |
| 10278322 | 10042835 | 1.56 | 69.5 | Adjuvant (A) | 2020-04-29 | 2020-05-01 | Rituximab + Venetoclax | 02 | null | ICON8B TRIAL | 100560447 |
| 10278678 | 10042836 | 1.51 | 69.3 | Palliative (P) | 2017-05-03 | 2017-05-12 | Carbo F | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100458409 |
| 10278761 | 10042837 | 1.53 | 73.5 | Palliative (P) | 2016-02-23 | 2016-03-01 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | FULVESTRANT + RIBOCICLIB | 100066444 |
| 10279310 | 10042840 | 1.75 | 95 | Palliative (P) | 2018-03-13 | 2018-03-15 | ABVD | 2 | N | PEG INTERFERON | 101385704 |
| 10279463 | 10042841 | 1.66 | 66 | Palliative (P) | 2018-02-01 | 2018-02-05 | ACELARATE Trial | N | N | LETROZOLE + PALBOCICLIB | 100152051 |
| 10280266 | 10042842 | 1.74 | 70 | Palliative (P) | null | 2018-12-01 | GEMCITABINE + NAB PACLITAXEL | null | null | PEG INTERFERON | 100528963 |
| 10280783 | 10042844 | 1.55 | 70 | Palliative (P) | 2017-06-28 | 2017-06-28 | ECX | 02 | N | FEC | 100115113 |
| 10281533 | 10042846 | 1.64 | 73.6 | Curative (C) | 2019-11-06 | 2019-11-08 | PLATFORM Trial | null | N | OBINUTUZUMAB + VENETOCLAX | 100107109 |
| 10282519 | 10042849 | 1.84 | 78.6 | null | 2017-04-07 | 2017-04-07 | CYTARABINE + DAUNORUBICIN | 02 | null | IXAZOMIB + LENALIDOMIDE | 100489531 |
| 10282528 | 10042850 | 0 | 65.5 | Palliative (P) | 2016-03-18 | 2016-06-16 | Carboplatin + Docetaxel | N | N | CVD | 101086635 |
| 10283968 | 10042852 | null | 75 | Palliative (P) | 2019-02-05 | 2019-02-22 | DA 3 + 10 | 02 | null | FEC | 100620638 |
| 10284501 | 10042854 | 1.8 | 66.5 | Palliative (P) | 2022-02-01 | 2022-02-10 | PCV | 02 | N | MELPHALAN | 101580750 |
| 10284652 | 10042855 | 0 | null | Palliative (P) | 2018-11-02 | 2018-11-04 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | N | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100409135 |
| 10284728 | 10042856 | 0 | 0 | 03 | 2020-02-02 | 2020-02-28 | Cisplatin + Etoposide po&iv 3 day | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101658494 |
| 10284744 | 10042857 | 1.63 | 71.4 | null | 2022-05-05 | 2022-05-09 | Apalutamide | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN | 100870164 |
| 10284794 | 10042858 | 1.71 | 80 | Adjuvant (A) | 2019-05-28 | 2019-06-12 | LENVATINIB | 02 | N | MATRIX LYMPHOMA TRIAL | 101036641 |
| 10285735 | 10042860 | 1.73 | 83.6 | null | 2019-11-14 | 2019-11-14 | Cisplatin + Radiotherapy | 02 | null | LUTETIUM-177 | 100919886 |
| 10285871 | 10042862 | 0 | null | Palliative (P) | 2017-06-15 | 2017-06-28 | null | N | null | ATEZOLIZUMAB + BEVACIZUMAB | 101175197 |
| 10286842 | 10042863 | 1.76 | 79.1 | Palliative (P) | 2019-05-29 | 2019-06-02 | Obinutuzumab + Venetoclax | 02 | null | APALUTAMIDE | 100832313 |